Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Health‐related quality of life (HRQoL) · women with early breast cancer
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Maternal death · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial),…
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): LMWH changes symptomatic thromboembolic events (timing of assessment unclear,… compared with UFH (very low certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial),…
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective or emergency (1 trial), elective cesarean only (1 trial),…
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): LMWH changes symptomatic DVT (timing of assessment unclear, within 6 weeks… compared with UFH (very low certainty).
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
Low‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Global assessment of treatment success · acute gout
Low‐dose colchicine showed no clear difference in participant global assessment of treatment success: Completely… compared with NSAIDs (low certainty).
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Disease progressionAssessed by: dilated assessment of the vertical C/D ratio using a 78 D lens · adults with PAC or PACG, and previous PI
1 finding from 1 review
Complications and side effects · Bell's palsy
It is very uncertain whether surgery for Bell's palsy changes side effects and complications of treatmentMeasured by clinical… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).
1 finding from 1 review